The leadership of Médecins sans Frontières (MSF) is under significant global pressure to reverse its decision to close its Access Campaign.

TAG calls on Danaher to lower the price of GeneXpert tests for TB and other diseases to $5 each and to commit to public transparency of the cost audit of Xpert MTB/RIF Ultra.
SIGN the Time for $5 Campaign petition!

The Food and Drug Administration (FDA) has granted traditional approval to Sirturo^® (bedaquiline) for use as part of combination therapy in adult and pediatric patients (5 years and older and weighing at least 15kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampin and isoniazid.

Public Health Action is the peer-reviewed quarterly open access journal of The International Union Against Tuberculosis and Lung Disease. It communicates and reports new knowledge across all relevant areas of operational research including: infection control, nutrition, TB, HIV, vaccines, smoking, COVID-19, microbial resistance and disease outbreaks.

Researchers from the Department of Bioengineering (BE), Indian Institute of Science (IISc), have designed a novel 3D hydrogel culture system that mimics the mammalian lung environment. It provides a powerful platform to track and study how tuberculosis bacteria infect lung cells and test the efficacy of therapeutics used to treat TB.

A fingerprint may soon be all a doctor needs to check whether tuberculosis patients are taking their antibiotics – thanks to a new study led by the University of Surrey.

Developing new TB vaccines by 2030 is within reach if decision-makers prioritize TB vaccine R&D as a signature piece of global health and AMR agendas.

24 June 2024, Tashkent, Uzbekistan --The Stop TB Partnership and WHO Regional Office for Europe have brought together 100 key stakeholders and partners from 13 countries of eastern Europe and central Asia for the first time since the United Nations High-Level Meeting last September, to discuss and debate the status of the tuberculosis (TB) airborne pandemic, the high rates of drug-resistant TB (DR-TB) and challenges towards ending this disease.

Members of the TB expert community (including civil society, affected community, doctors, nurses, researchers, policymakers, etc.) are invited to take part in the second round of a Delphi survey, led by the London School of Hygiene & Tropical Medicine, exploring the opportunities and value of offering non-TB services for people with TB and their household contacts.

National TB programs in 13 countries worked with WHO/Europe from 2020 to 2023 to examine treatment outcomes for people on 9-month treatment regimens for MDR-TB.